Cisplatin in cancer therapy: molecular mechanisms of action
about
Molecular mechanisms of cisplatin resistance in cervical cancerRole of endoplasmic reticulum stress in drug-induced toxicityCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesUnusual mode of protein binding by a cytotoxic π-arene ruthenium(ii) piano-stool compound containing an O,S-chelating ligandDrugging the addict: non-oncogene addiction as a target for cancer therapyEngineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic DeliveryTCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cellsRevealing Three Stages of DNA-Cisplatin Reaction by a Solid-State NanoporeUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyChemical Swarming: Depending on Concentration, an Amphiphilic Ruthenium Polypyridyl Complex Induces Cell Death via Two Different MechanismsNrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxiaMechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian CancerColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal CancerA case of chronic hypomagnesemia in a cancer survivor.Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells.Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapyPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.DEC2 expression antagonizes cisplatin‑induced apoptosis in human esophageal squamous cell carcinomaChromatin Regulates Genome Targeting with Cisplatin.Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung CancerMetabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cellsInduction of Cell Cycle Arrest and Apoptosis by Physcion, an Anthraquinone Isolated From Rhubarb (Rhizomes of Rheum tanguticum), in MDA-MB-231 Human Breast Cancer Cells.RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo.Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cellsAgrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma.DNA repair mechanisms in cancer development and therapySynthesis and antiproliferative activity of glutamic acid-based dipeptides.Association between Programmed Cell Death 6 Interacting Protein Insertion/Deletion Polymorphism and the Risk of Breast Cancer in a Sample of Iranian Population.Elemental bioimaging of Cisplatin in Caenorhabditis elegans by LA-ICP-MSSmall-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation.A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells.Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells.Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents.Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.A first-in-class and a fished out anticancer platinum compound: cis-[PtCl2(NH3)2] and cis-[PtI2(NH3)2] compared for their reactivity towards DNA model systems.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
P2860
Q26746228-129E711C-E4FA-41B5-AE6C-00078EA61161Q26765518-5D7D8843-0E05-41F3-9DC7-DE72829AEBEAQ26863779-FC152678-2E25-495E-890D-2394A0B9D02AQ27720200-338D6DD1-AF80-48BC-AD35-9C5321B934AAQ28079559-F4C2B66A-CC9C-4A87-856F-C5B3DD5ADFC7Q28087367-7DC3DD58-4EE6-4280-992D-261DBA7E0C83Q28118898-8177C51E-3910-41BA-AB51-5E41D0DA23ACQ28647465-579E3EEF-1045-4AFD-B2D7-D2FAEC465434Q28818313-060FD777-13F7-433C-8CC6-DC881AA69394Q28822145-84A5597C-675D-4514-A580-7E7F0168DCB8Q28828596-5A5117F5-D326-4162-B4C9-297220E4B63DQ29247912-700A6D4D-FEC9-464B-9181-B806379B42D6Q30238915-F337B686-DF6F-4D8B-92BA-C95FC33653ECQ33168174-94E04D67-636B-4980-BCC2-148DD3408AB5Q33597807-D7A3AB97-0AED-4523-A4F6-79A30ABDCFE2Q33638206-C7BB4DA9-B75A-434A-8999-7A93428E75A8Q33685402-AC0A318E-69D1-4FE8-80CA-9B87BC8E91E0Q33739235-52078EF6-945D-409C-A34D-B62664218CD3Q33744706-6F5B5D0D-2286-4238-A9C5-0CEEF7C6E300Q33827950-6C39523B-B2FB-4275-9C1C-F25D97181BE5Q33845705-73541073-CEAF-4678-8B7B-66CEA6DCCC1CQ33854715-3DCD8A33-BA0D-4C61-9DBD-9AFB163E072BQ33895232-B2F94F9F-5488-4A05-8E4E-76C221CE68C0Q34853169-A2AC50DD-1B54-4EB0-BF99-43854497E8AAQ34956767-95782DD1-AEFC-4ABF-9688-3271D83203EFQ35232784-D4ACA003-4C56-4BEF-9B33-B4CC3EE7EC7DQ35290630-97DF0FA3-7317-434F-A928-A999CD434495Q35519929-F3535699-858E-40FA-A19F-5254743E719FQ35531287-591691C8-9263-42E3-99FC-7590A8C73B4BQ35611178-4081152A-D0C7-4B2F-ACE3-843857C80599Q35612572-C3108A53-8FF8-4206-86EB-2544AFD23ADCQ35638073-3A186877-238C-47F2-8CC0-DCE1FD574F12Q35743521-7C9EEDAB-F2B5-4BB2-91DB-369FE820A195Q35754482-E264463C-44A4-4A64-822F-083634FD9546Q35847932-A532450E-8D65-47D2-85F6-0DEA6DE229BBQ35871264-3CD8E3C4-5949-4FD0-B297-692961527F17Q35904230-CFFC6B56-C90C-419E-B715-F688DAB1F63CQ35917300-8563E301-A129-463F-91C6-2B8DBA293926Q36002521-E3D2D31E-ED44-4B42-AA3B-AEE323BBA80FQ36020882-623A53F8-9D2A-47B1-BC7B-5E9BE41D4EAE
P2860
Cisplatin in cancer therapy: molecular mechanisms of action
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Cisplatin in cancer therapy: molecular mechanisms of action
@ast
Cisplatin in cancer therapy: molecular mechanisms of action
@en
Cisplatin in cancer therapy: molecular mechanisms of action
@nl
type
label
Cisplatin in cancer therapy: molecular mechanisms of action
@ast
Cisplatin in cancer therapy: molecular mechanisms of action
@en
Cisplatin in cancer therapy: molecular mechanisms of action
@nl
prefLabel
Cisplatin in cancer therapy: molecular mechanisms of action
@ast
Cisplatin in cancer therapy: molecular mechanisms of action
@en
Cisplatin in cancer therapy: molecular mechanisms of action
@nl
P2860
P1476
Cisplatin in cancer therapy: molecular mechanisms of action
@en
P2093
Paul Bernard Tchounwou
Shaloam Dasari
P2860
P304
P356
10.1016/J.EJPHAR.2014.07.025
P407
P577
2014-07-21T00:00:00Z